口服无环膦酸核苷前药:阿德福韦酯和他的(POC)PMPA

{"title":"口服无环膦酸核苷前药:阿德福韦酯和他的(POC)PMPA","authors":"M. Arimilli, J. Dougherty, K. Cundy, N. Bischofberger","doi":"10.1016/S1075-8593(99)80004-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"3 1","pages":"69-91"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(99)80004-5","citationCount":"7","resultStr":"{\"title\":\"Orally bioavailable acyclic nucleoside phosphonate prodrugs: Adefovir dipivoxil and bis(POC)PMPA\",\"authors\":\"M. Arimilli, J. Dougherty, K. Cundy, N. Bischofberger\",\"doi\":\"10.1016/S1075-8593(99)80004-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":92864,\"journal\":{\"name\":\"Advances in antiviral drug design\",\"volume\":\"3 1\",\"pages\":\"69-91\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1075-8593(99)80004-5\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in antiviral drug design\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/S1075-8593(99)80004-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in antiviral drug design","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/S1075-8593(99)80004-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}